Home > Publications database > Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial. > print

001     143613
005     20240229112600.0
024 7 _ |a 10.1038/s41408-019-0206-8
|2 doi
024 7 _ |a pmid:30962424
|2 pmid
024 7 _ |a pmc:PMC6453945
|2 pmc
024 7 _ |a altmetric:58747113
|2 altmetric
037 _ _ |a DKFZ-2019-01190
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Weisel, Katja C
|b 0
245 _ _ |a Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial.
260 _ _ |a London [u.a.]
|c 2019
|b Nature Publishing Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1558421238_12308
|2 PUB:(DE-HGF)
|x Letter
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Scheid, Christof
|b 1
700 1 _ |a Zago, Manola
|b 2
700 1 _ |a Besemer, Britta
|b 3
700 1 _ |a Mai, Elias K
|0 0000-0002-6226-1252
|b 4
700 1 _ |a Haenel, Mathias
|b 5
700 1 _ |a Duerig, Jan
|b 6
700 1 _ |a Munder, Markus
|b 7
700 1 _ |a Lindemann, Hans-Walter
|b 8
700 1 _ |a Seckinger, Anja
|b 9
700 1 _ |a Kunz, Christina
|0 P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2
|b 10
|u dkfz
700 1 _ |a Benner, Axel
|0 P:(DE-He78)e15dfa1260625c69d6690a197392a994
|b 11
|u dkfz
700 1 _ |a Hose, Dirk
|b 12
700 1 _ |a Jauch, Anna
|b 13
700 1 _ |a Salwender, Hans
|b 14
700 1 _ |a Goldschmidt, Hartmut
|b 15
773 _ _ |a 10.1038/s41408-019-0206-8
|g Vol. 9, no. 4, p. 45
|0 PERI:(DE-600)2600560-8
|n 4
|p 45
|t Blood cancer journal
|v 9
|y 2019
|x 2044-5385
909 C O |o oai:inrepo02.dkfz.de:143613
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)e15dfa1260625c69d6690a197392a994
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2019
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BLOOD CANCER J : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b BLOOD CANCER J : 2017
920 1 _ |0 I:(DE-He78)C060-20160331
|k C060
|l Biostatistik
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C060-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21